LN-145 vs Olvimulogene nanivacirepvec

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: No discrete molecular target · full Non-Small Cell Lung Cancer pipeline

LN-145

Developed by Iovance Biotherapeutics

Phase 2 in Non-Small Cell Lung Cancercell therapy
Weak signal

NCT03645928 · Phase 2 · terminated

This open-label study gave tumor-infiltrating lymphocyte therapy (lifileucel or LN-145), alone or combined with checkpoint inhibitors, to patients with advanced melanoma, head-and-neck cancer or non-small-cell lung cancer across multiple non-randomized treatment cohorts, with objective response rate as the primary measure. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2030 · NCT04614103 (registry estimate)

Reported efficacy

Objective Response Rate (Up to 60 months); Safety Profile Measured by Grade ≥3 TEAEs (Up to 60 months); Percentage of patients for whom lifileucel is successfully manufactured and meets release specification (Up to 60 months): Cohort 3B (NSCLC) interim data, objective response rate: 21.4% in the full analysis set (n=28), 25% in the efficacy-evaluable set (n=24); one complete response and five partial responses.

Result source: NCT03645928

Olvimulogene nanivacirepvec

Developed by Genelux Corporation and partners

Phase 2 in Non-Small Cell Lung Canceroncolytic virus
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: February 2027 · NCT06463665 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLN-145Olvimulogene nanivacirepvec
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
Duration of response, median—Not reported—Not reported

PFS, median

LN-145
—Not reported
Olvimulogene nanivacirepvec
—Not reported

OS, median

LN-145
—Not reported
Olvimulogene nanivacirepvec
—Not reported

ORR

LN-145
—Not reported
Olvimulogene nanivacirepvec
—Not reported

Duration of response, median

LN-145
—Not reported
Olvimulogene nanivacirepvec
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Olvimulogene nanivacirepvec: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

LN-145

Overall 21.4%
responder rate · % of participants
No placebo or comparator arm
NCT03645928 · Phase 2 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LN-145's landscape · Olvimulogene nanivacirepvec's landscape